Do you have a diagnosis of heart failure, had an Echocardiogram in the last 12 months and are you 18 years or older? HERMES is a trial of ziltivekimab, a drug to target inflammation, for patients with heart failure (HF) and reduced or preserved ejection fraction. Ziltivekimab may help:
- Decrease the risk of cardiovascular events.
- Improve heart function.
- Enhance overall quality of life for patients with HF.
Find out if you or your loved one qualifies;
Contact: Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Do you have a diagnosis of heart failure?
Had an Echocardiogram in the last 12 months?
Are you 18 years or older? Hermes is a trial of ziltivekimab, a drug to target inflammation, for patients with heart failure (HF) and reduced or preserved ejection fraction.
By reducing inflammation, ziltivekimab may help:
- Decrease the risk of cardiovascular events.
- Improve heart function.
- Enhance overall quality of life for patients with HF.
Find out if you or your loved one qualifies; Contact:Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206 nshctrials@gmail.com
Are you 65 or older with a diagnosis of Atrial Fibrillation (AF) or flutter?
Do you have a condition associated with increased risk of bleeding?
Are you planning the use of Aspirin or other antiplatelet agent? LILAC-TIMI 76 (ANT-010): is a phase lll trial of abeLacimab in the prevention of stroke and systemic embolism in high-risk patients with aFibwho have been deemed unsuitable for oral anticoagulation therapy.
Find out if you or your loved one qualifies; Contact: Charmaine Waters, BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Are you 65 or older with a diagnosis of Atrial Fibrillation (AF) or flutter?
Do you have a condition associated with increased risk of bleeding?
Are you planning the use of Aspirin or other antiplatelet agent? LILAC-TIMI 76 (ANT-010): is a phase lll trial of abeLacimab in the prevention of stroke and systemic embolism in high-risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation therapy.
Find out if you or your loved one qualifies; Contact: Charmaine Waters, BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Are you 18 years or older and hospitalized or recently discharged with a primary diagnosis of heart failure showing signs and symptoms of heart failure at the time of hospital admission??
Do you have mildly reduced or preserved ejection fraction EF (40% or higher)?
FINALITY-HF trial aims to test the effectiveness and safety of a drug called finerenone in patients with heart failure who have a mildly reduced or preserved heart function (40% or higher) in patients hospitalized due to an episode of Heart Failure.
Participants will be monitored for changes in their heart function and overall health.
The main goals are to see if finerenone can reduce future heart failure, cardiovascular events and hospitalizations.
Find out if you or your loved one qualifies;
Contact: Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Are you 18 years or older and hospitalized or recently discharged with a primary diagnosis of heart failure?
Have mildly reduced or preserved ejection fraction EF (40% or higher)?
Show signs and symptoms of heart failure at the time of hospital admission?
FINALITY-HF trial aims to test the effectiveness and safety of a drug called finerenone in patients with heart failure who have a mildly reduced or preserved heart function (40% or higher) in patients hospitalized due to an episode of Heart Failure.
Participants will be monitored for changes in their heart function and overall health.
The main goals are to see if finerenone can reduce future heart failure, cardiovascular events and hospitalizations.
Find out if you or your loved one qualifies;
Contact: Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Are you 18 years or older with a diagnosis of heart failure with reduced ejection fraction?
Are you NOT able to take certain heart medications like spironolactone? REDEFINE-HF trial aims to test the effectiveness and safety of a drug called finerenone in patients with heart failure who can't take certain other heart medications.
Participants are randomly assigned to receive either finerenone or a placebo.
The main goals are to see if finerenone can reduce future heart failure, cardiovascular events and hospitalizations.
Find out if you or your loved one qualifies;
Contact: Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Are you 18 years or older?
Do you have heart failure with reduced ejection fraction?
Are you NOT able to take certain heart medications like spironolactone? REDEFINE-HF trial aims to test the effectiveness and safety of a drug called finerenone in patients with heart failure who can't take certain other heart medications.
Participants are randomly assigned to receive either finerenone or a placebo.
The trial will last for a specific period, during which participants will be monitored for changes in their heart function and overall health.
The main goals are to see if finerenone can reduce future heart failure, cardiovascular events and hospitalizations.
Find out if you or your loved one qualifies;
Contact: Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Are you 45 years or older and managing your LDL-C with medical and dietary treatment?
Have you experienced a recent heart attack or been hospitalized with angina? DAL-302: is a trial to test effectiveness and safety of dalcetrapib, a drug that may reduce the risk of heart attacks in people who have a certain genotype and have recently experienced acute coronary syndrome.
Find out if you or your loved one qualifies; Contact: Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
Are you 45 years or older?
Managing your LDL-C with medical and dietary treatment?
Have experienced a recent heart attack or hospitalized with angina? dal-GenE-2: is a trial to test effectiveness and safety of dalcetrapib, a drug that may reduce the risk of heart attacks in people who have a certain genotype and have recently experienced acute coronary syndrome.
Find out if you or your loved one qualifies; Contact: Charmaine Waters BScN,
Clinical Trial Coordinator 604 831-1206
nshctrials@gmail.com
